Clinical Trials Browser

Phase 2 × Withdrawn × Isotretinoin × Clear all

NCT04909515 2022-09-01

Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission.

Phase 2 Withdrawn

CNS

Neuroblastoma

NCT00003405 2021-10-14

Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia

Phase 2 Withdrawn

Other hematologic neoplasm

Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

NCT01048086 2016-06-21

90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET)

Phase 2 Withdrawn

CNSEndocrineNET

Neuroblastoma, Neuroendocrine Tumors